C4X Discovery Holdings Ltd. has selected a preclinical candidate from its oral α4β7 integrin inhibitor program for the treatment of inflammatory bowel disease (IBD). The potent and selective α4β7 ...
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of ...
A new review reveals how focal adhesion kinase (FAK) acts as a central regulator of tumor progression and immune suppression ...
Panelists discuss several promising new agents for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF), including an LPA1 receptor antagonist showing lung function ...
Eli Lilly has agreed to acquire Morphic Therapeutic for approximately $3.2 billion, the companies said today, in a deal designed to bolster the buyer’s pipeline with chronic disease candidates led by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results